The face of the pharmaceutical sector has for a long time been that of Big Pharma. But in Boston, biotech now includes small, boutique firms with just a few employees — even just one employee — focused on just one or two treatment lines. We take a look at the changing landscape of biotech firms.
- Michael Gilman, founder and CEO, Stromedix
- Scott Kirsner, innovation columnist, Boston Globe
- Curt Nickish, business and technology reporter, WBUR
This segment aired on May 31, 2011.